* Cash and cash equivalents at EUR31.2 million, short-term deposits at EUR0.05
million(2), and long-term deposit at EUR9.3 million(3) as of June 30, 2023,
compared to EUR86.7 million, EUR1.0 million and EUR0.7 million as of December

    31, 2022, respectively
  * Revenues of EUR1.9 m in H1 2023, compared to EUR0.1 million for the same period
    in 2022

Daix (France), Long Island City (New York, United States), July 27, 2023 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today reported
certain preliminary financial results for the first half of 2023, including its cash, cash equivalents, and revenues, and provided a corporate update.
Preliminary Financial Results

As  of June 30, 2023, the Company's cash  and cash equivalents amounted to EUR31.2
million,  short-term deposits to 0.05 million(2),  and long-term deposit to EUR9.3
million(3),  compared  to  EUR86.7  million,  EUR1.0  million and EUR0.7 million as of

December 31, 2022, respectively.
The EUR48.0 million decrease in cash and cash equivalents between June 30, 2023 and December 31, 2022 is mainly due to increased cash used in operating activities and reflects the 2023 planned acceleration of the clinical development activities mostly driven by costs associated with the NATiV3 Phase III clinical trial of lanifibranor in NASH, and, to a lesser extent, with the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and type 2 diabetes ("T2D").
Net cash used in operating activities amounted to (EUR45.2) million in the first
half of 2023, compared to (EUR26.2) million for the same period in 2022. R&D
expenses for the first half of 2023 were up 81 % compared to the first half of
2022. This increase is in line with the clinical development activities planned
in 2023.
Net cash used in investing activities for the first half of 2023 amounted to
(EUR7.7) million, compared to (EUR0.3) million in the first half of 2022. The change
is mostly due to the change in deposits between both periods.
Net cash used in financing activities for the first half of 2023 amounted to
(EUR2.2) million, compared to net cash provided by financing activities of EUR14
million in the first half of 2022. The net cash generated in financing
activities in 2022 was mainly driven by the equity raised through the Company's
At-The-Market Program for approximately EUR9.4 million (gross proceeds) in June
2022, and three loan agreements with a syndicate French banks for a total amount
of EUR5.3 million entered into in the first half of 2022. In the first half of
2023, the net cash used in financing activities was mainly due to loan
reimbursement and medical imaging equipment debt rents.
Over the first half of 2023, the Company recorded a negative exchange rate
effect on cash and cash equivalents of (EUR0.4) million, compared to a positive
effect of EUR2.4 million for the first half of 2022, due to the evolution of
EUR/USD exchange rate.
Considering its current R&D and clinical development programs, the Company estimates that its existing cash, cash equivalents and deposits should allow the
Company to fund its operations until the end of the fourth quarter of 2023(4).
Revenues
The Company's revenues for the first half of 2023 amounted to EUR1.9 million, as
compared to EUR0.1 million for the same period in 2022. The increase is mainly due
to the receipt of the first regulatory milestone payment from CTTQ, Sino Biopharm's subsidiary, which was received in July 2023. The milestone payment was triggered in May 2023 after CTTQ received the Investigational New Drug ("IND") approval from the Chinese National Medical Products Administration ("NMPA") to initiate the clinical development in mainland China of lanifibranor in NASH.
***
Business updates
Inventiva announced positive topline results of the Phase II clinical trial conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor 800mg/daily in patients with NAFLD and T2D. Lanifibranor 800mg
achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy following 24 weeks of treatment in patients with non-alcoholic fatty liver disease (NAFLD). A significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as NAFLD resolution with lanifibranor compared to
placebo. Lanifibranor treatment significantly improved both hepatic and peripheral insulin sensitivity, which translated into better glycemic control. The study met multiple secondary metabolic endpoints confirming the cardiometabolic benefit of lanifibranor in patients with NAFLD, and ability to improve adipose tissue function. The study confirmed the favorable safety and tolerability profile of lanifibranor.
Recruitment for our pivotal Phase III trial NATiV3 of lanifibranor in non- cirrhotic NASH continues with 389 sites activated in 23 countries, as of July 27, 2023. The previously announced revised study design which limits the duration of the trial to 120 weeks instead of up to 7 years, reduces the number of biopsies from three to two, and includes a 48-week active treatment extension
study, has been approved in 16 countries and approximately 70% of activated sites are currently operating under the revised design. This new patient friendly design is improving the patient enrollment rate which has doubled since
implementation in sites where the revised design has been in place for more than
3 months. In addition, the screen failure rate has been improving since September 2022. In China, our partner CTTQ, after receiving the IND approval from the NMPA on May 22 2023, has opted to join NATiV3 and we are actively working with our partner to activate 50 sites in mainland China and 2 sites in Hong Kong.
As of July 27, 2023, the percentage of patients randomized and those having successfully met all recruitment criteria, is approximately of 50% of the planned enrollment in NATiV3 and we are targeting the last patient first visit by the end of the second half of 2023.
Two Data and Safety Monitoring Board ("DSMB") meetings have taken place, both with recommendations to continue the study without any modification to the protocol. Of note the safety profile is consistent with what was observed in previous clinical trials with lanifibranor.
The baseline characteristics of the patients enrolled so far are aligned with expectations and the baseline characteristics of patients enrolled in the NATIVE
Phase IIb trial. The main difference is a higher percentage of patients with T2D
thus far in NATiV3 compared to NATIVE Phase IIb (58% vs 42% respectively). The effect size of lanifibranor therapy over placebo in the Phase IIb clinical trial
on the composite endpoint 'NASH resolution and fibrosis improvement', which corresponds to the primary efficacy endpoint in the Phase III NATiV3 clinical trial, was higher in patients with T2D versus patients who did not have diabetes: 21% and 26% for lanifibranor 800 and 1200 mg/day, respectively, in patients with T2D versus 7% and 22%, respectively, in patients who did not have diabetes(5).
We are also continuing recruitment in the Phase II proof of concept clinical trial LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with NASH and T2D. Recruitment of patients has been slower than expected and topline results are now targeted for the end of the first quarter of 2024 compared to the second half of 2023 as previously announced.
Next key milestones expected
* Publication of the topline results of the LEGEND Phase IIa combination trial

    of lanifibranor in combination with empagliflozin in patients with NASH and
    T2D - targeted for the end of the first quarter of 2024
  * Last Patient First Visit of the NATiV3 Phase III clinical trial evaluating
    lanifibranor in NASH - targeted by the end of the second half of 2023

Upcoming investor conference participation

  * H.C. Wainwright 25th Annual Global Investment Conference - New York,
    September 11-13
  * Lyon Pôle Bourse - Lyon - September 27th
  * Stifel 2023 Healthcare Conference - New York, November 14-15

Upcoming scientific conference participation
* XXVIII ALEH Congress (Asociación Latinoamericana para el Estudio del Hígado)

    - Bogota, Colombia - August 29(th)-September 1(st)
  * Paris NASH meeting - Paris - September 7-9
  * AASLD - The Liver Meeting - Boston - November 10-14

Next financial results publication

  * Financial results for the first nine months of 2023: Thursday, September
    28, 2023 (after U.S. market close)

About Inventiva
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with NASH, mucopolysaccharidoses ("MPS") and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.
Inventiva's lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH,
a common and progressive chronic liver disease for which there are currently no approved therapies.
Inventiva's pipeline also includes odiparcil, a drug candidate for the treatment
of adult MPS VI patients. As part of Inventiva's decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting an oncology development candidate for its Hippo signaling pathway program.
The Company has a scientific team of approximately 90 people with deep expertise
in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules,
approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
Inventiva is a public company listed on compartment B of the regulated market of
Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market
in the United States (ticker: IVA). www.inventivapharma.com (http://www.inventivapharma.com/)
Contacts

                   Brunswick Group
 Inventiva         Tristan Roquet
                   Montegon /
 Pascaline Clerc   Aude Lepreux /
 VP of Global      Matthieu Benoist
 External Affairs  Relations médias

media@inventivaph inventiva@brunswickgro Westwicke, an ICR Company
arma.com up.com Patricia L. Bank
(mailto:media@inv (mailto:inventiva@brun Relations investisseurs

 entivapharma.com) swickgroup.com)        patti.bank@westwicke.com
    +1 240 620
 9175                  +33 1 53 96 83 83           +1 415 513-1284

Important Notice
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but
are not limited to preliminary unaudited financial results for Inventiva's half-
year ended June 30, 2023, forecasts and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including design, duration, timing, recruitment costs, screening and enrollment for those trials, including the ongoing NATiV3 Phase III clinical trial with lanifibranor in NASH and the LEGEND
Phase IIa combination trial with lanifibranor and empagliflozin in patients with
NASH and type 2 diabetes, potential development of and regulatory pathway for odiparcil, clinical trial data releases and publications, the information, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits, and safety profile of Inventiva's product candidates, including lanifibranor, potential regulatory submissions and approvals, and Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans, growth and prospects of Inventiva, the potential receipt of the second tranche under the EIB loan and any potential transaction or receipt of additional funds, future access to the two year short term deposit, and the sufficiency of Inventiva's cash resources and estimated cash runway. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", "designed", "hopefully", "target", "aim", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from
the anticipated future results, performance or achievements expressed or implied
by such statements, forecasts and estimates, due to a number of factors, including the completion of financial closing procedures, final adjustments and other developments that may arise that could cause the preliminary financial results for first half of 2023 to differ from the financial results that will be
reflected in Inventiva's financial statements for the half-year ended June 30, 2023, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue
as a going concern, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results
of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva's expectations with respect to the changes to the clinical development plan for lanifibranor for the treatment of NASH may not be realized and may not support the approval of a New Drug Application, Inventiva may encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventiva to recruit and retain patients in clinical
studies, enrollment and retention of patients in clinical trials is an expensive
and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential,
Inventiva faces substantial competition and Inventiva's business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by geopolitical events, such as the conflict between Russia and Ukraine, related sanctions and related impacts and potential impacts on the initiation, enrollment and completion of Inventiva's clinical trials on anticipated timelines, health epidemics, and macroeconomic conditions, including
global inflation, rising interest rates, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers
are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the Universal Registration Document for the year ended December
31, 2022 filed with the Autorité des Marchés Financiers on March 30, 2023, and
the Annual Report on Form 20-F for the year ended December 31, 2022 filed with
the Securities and Exchange Commission on March 30, 2023 for other risks and
uncertainties affecting Inventiva, including those described from time to time
under the caption "Risk Factors". Other risks and uncertainties of which
Inventiva is not currently aware may also affect its forward-looking statements
and may cause actual results and the timing of events to differ materially from
those anticipated.
All information in this press release is as of the date of the release. Except
as required by law, Inventiva has no intention and is under no obligation to
update or review the forward-looking statements referred to above. Consequently,
Inventiva accepts no liability for any consequences arising from the use of any
of the above statements.
(1) Preliminary non-audited financial information.
(2) Short-term deposits are included in the category "other current assets" in the IFRS consolidated statement of financial position, and are considered by the
Company as liquid and easily available.
(3) The long term deposit has a two year term accessible prior to the expiration
of the term with a notice period of 31 days and is considered as liquid by the Company.
(4) This estimate is based on the Company's current business plan and excludes any potential milestones payable to or by the Company and any additional expenditures related to the potential continued development of the odiparcil program or resulting from the potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the
Company may pursue. The Company may have based this estimate on assumptions that
are incorrect, and the Company may end up using its resources sooner than anticipated. This estimate does not take into consideration the EUR25 million
second tranche of the loan agreement from the EIB, which is subject to certain conditions. The disbursement of the second tranche of EUR25 million is subject to,
among other conditions, (i) the Company issuing warrants to EIB in accordance with the terms and conditions of the warrants agreements entered into July 1, 2022, (ii) the full drawdown of the first tranche, (iii) the receipt by the Company from the date of the EIB credit facility of an aggregate amount of at least EUR70.0 million (inclusive of the EUR18.0 million that was a condition for the
disbursement of the first tranche), paid either in exchange for Company shares, or through upfront or milestone payments, (iv) an out-licensing, partnership or royalty transaction with an upfront payment of at least EUR10.0 million (condition
that has been met with the signature of the licensing agreement of lanifibranor with Sino Biopharm/CTTQ)? and (v) operational criteria based on patient enrollment and number of sites activated in the Company's NATiV3 Phase III clinical trial of lanifibranor in patients with NASH.
(5)Efficacy of the panPPAR agonist lanifibranor on the histological endpoints NASH resolution fibrosis regression is similar in type-2 diabetic and non- diabetic patients: additional results of the NATIVE Phase 2b trial in non- cirrhotic NASH - Poster AASLD diabetes 2020 Final (inventivapharma.com) (https://inventivapharma.com/wp-content/uploads/2020/12/poster-AASLD-diabetes-
2020-Final-Lecture-seule-3.pdf)
Â